Evaxion and pantherna announce promising preclinical mrna vaccine data

Copenhagen, denmark and hennigsdorf, germany, feb. 08, 2023 (globe newswire) -- evaxion biotech a/s (nasdaq: evax) (“evaxion” or the “company”), a clinical-stage biotechnology company specializing in the development of ai-powered immunotherapies and pantherna therapeutics gmbh (“pantherna”), a biopharmaceutical company developing advanced nanoparticle solutions for the delivery and expression of mrna therapeutics, today announced preclinical proof of concept for the combination of the two companies' key technologies.
EVAX Ratings Summary
EVAX Quant Ranking